{"id":61409,"date":"2026-03-26T15:35:59","date_gmt":"2026-03-26T07:35:59","guid":{"rendered":"https:\/\/flcube.com\/?p=61409"},"modified":"2026-03-26T15:36:00","modified_gmt":"2026-03-26T07:36:00","slug":"united-laboratories-novo-nordisk-report-positive-phase-ii-data-for-ubt251-triple-glp-1-gip-gcg-agonist-achieves-19-7-weight-los","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61409","title":{"rendered":"United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 \u2013 Triple GLP-1\/GIP\/GCG Agonist Achieves 19.7% Weight Los"},"content":{"rendered":"\n

Partners United Laboratories International Holdings Ltd<\/strong> (HKG: 3933<\/a>) and Novo Nordisk (NYSE: NVO<\/a>)<\/strong> announced positive topline results<\/strong> from a Phase II clinical trial in China<\/strong> evaluating UBT251<\/strong> for weight management<\/strong>. The long-acting synthetic peptide triple receptor agonist<\/strong> (targeting GLP-1, GIP, and glucagon receptors<\/strong>) demonstrated 19.7% mean weight loss (-17.5 kg)<\/strong> at 24 weeks vs. 2.0% placebo<\/strong>, with statistically significant improvements in metabolic parameters<\/strong> and a favorable safety profile<\/strong>.<\/p>\n\n\n\n

Phase II Study Results<\/h2>\n\n\n\n
Endpoint<\/th>UBT251 (6 mg)<\/th>Placebo<\/th>Clinical Significance<\/th><\/tr><\/thead>
Mean Weight Loss<\/strong><\/td>19.7% (-17.5 kg)<\/strong><\/td>2.0% (-1.6 kg)<\/td>17.7 percentage-point advantage<\/strong>; competitive with tirzepatide\/zepbound<\/td><\/tr>
Baseline Weight<\/strong><\/td>92.2 kg (mean)<\/td>92.2 kg<\/td>Typical Chinese overweight\/obese population<\/td><\/tr>
Dosing Regimen<\/strong><\/td>Once-weekly (2, 4, 6 mg tested)<\/td>\u2014<\/td>6 mg optimal dose<\/strong> identified<\/td><\/tr>
Treatment Duration<\/strong><\/td>24 weeks<\/td>24 weeks<\/td>Early efficacy signal; durability TBD<\/td><\/tr>
Key Secondary Endpoints<\/strong><\/td>Waist circumference, blood glucose, blood pressure, lipids<\/td>\u2014<\/td>Comprehensive metabolic benefits<\/strong> beyond weight<\/td><\/tr>
Safety\/Tolerability<\/strong><\/td>Generally safe and well tolerated<\/td>\u2014<\/td>Supports Phase III advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Partnership Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Agreement Date<\/strong><\/td>March 2025<\/td><\/tr>
United Laboratories<\/strong><\/td>Development responsibility: Mainland China, Hong Kong, Macau, Taiwan<\/strong><\/td><\/tr>
Novo Nordisk<\/strong><\/td>Development responsibility: Rest of world<\/strong> (ex-Greater China)<\/td><\/tr>
Product<\/strong><\/td>UBT251 \u2013 synthetic peptide triple agonist (GLP-1\/GIP\/GCG)<\/td><\/tr>
Format<\/strong><\/td>Long-acting, once-weekly injection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Position<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Triple Agonist Mechanism<\/strong><\/td>GLP-1 (satiety) + GIP (potentiation) + GCG (energy expenditure)<\/strong> \u2013 potentially superior to dual agonists (tirzepatide) via added metabolic effect<\/td><\/tr>
Weight Loss Efficacy<\/strong><\/td>19.7% at 24 weeks<\/strong> approaches tirzepatide SURMOUNT-1 data (20.9% at 72 weeks)<\/strong> \u2013 suggests competitive or superior early efficacy<\/td><\/tr>
China Market Priority<\/strong><\/td>United Labs leads China development<\/strong> \u2013 addresses ~200 million obese adults<\/strong> with localized regulatory and commercial strategy<\/td><\/tr>
Novo Nordisk Global Rights<\/strong><\/td>Leverages Wegovy\/Ozempic infrastructure<\/strong> for ex-China; UBT251 potential next-gen successor<\/strong> to semaglutide\/tirzepatide<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Lilly’s retatrutide (triple agonist)<\/strong> Phase III ongoing; UBT251 positions as Novo’s triple agonist response<\/strong> with differentiated PK profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n